博腾股份标普ESG评分稳步提升

Swipe Left for English News→

标普全球企业可持续发展评估（S&P Global Corporate Sustainability Assessment）于近日公布新一轮环境、社会及公司治理（ESG）评分结果（截至2025年11月12日），重庆博腾制药科技股份有限公司（股票简称：博腾股份，股票代码：300363）评分由44分提升至50分。

从具体维度来看，公司环境、社会、治理与经济三个维度的ESG评分分别提升12分、5分、3分，其中在能源管理、废弃物与污染物管理、水资源管理、应对气候变化、供应链管理等指标评分均获得较大进步。

博腾股份秉持“做绿色公民、促共同进步、筑健康社会、优公司治理”四大核心ESG理念，深度推动ESG融入企业战略和经营，不断强化实质性议题管理。2025年，公司围绕ESG工作多点发力：在目标承诺层面，公司科学碳目标已获SBTi（the Science Based Targets initiative）认证，并发布涵盖能源、水资源和废弃物管理三大板块的环境目标，以目标牵引管理措施落地；在管理制度层面，公司制定并发布《供应商行为准则》，进一步推动供应链管理体系完善；在人员能力层面，公司组织开展碳核查、可持续供应链等专项培训，持续提升员工ESG管理认知和专业技能。

未来，公司将继续践行ESG发展理念，持续完善ESG全生命周期管理体系，以更系统、更深入的举措，推动公司更具韧性的高质量可持续发展。

博腾股份成立于2005年，主要为全球药企、生物科技公司、科研机构等提供从临床前研究到药品上市全生命周期所需的小分子药物、多肽与寡核苷酸药物、蛋白与偶联药物以及细胞与基因治疗药物等一站式服务解决方案，研发、生产、运营场地覆盖中国（重庆、上海、四川、江苏、江西、湖北）、美国、斯洛文尼亚、比利时、瑞士和丹麦等地。我们终坚持以客户为中心，致力于为客户提供创新、可靠的全球化、端到端CDMO服务，让好药更早惠及大众。

Porton Pharma Solutions Ltd. (hereinafter “Porton”) is glad to announce that it scored 50 in the 2025S&P Global Corporate Sustainability Assessment reflecting an improvement of 6 points over the previous assessment, where scores in all the three dimensions getting improved (ESG Score as of 12/11/2025).

In this year’s assessment, Porton’s scores in Environmental, Social and Governance & Economic dimensions increase by 12, 5, and 3 points respectively. Notable progress was made in criteria such as Energy, Waste & Pollutants, Water, Climate Strategy, and Supply Chain Management.

Adhering to the ESG concepts of "Green Development, Promote Common Progress, build a Healthy Society, and Enhance Corporate Governance", Porton is committed to integrating ESG into its corporate strategy and operations, and continuously strengthens the management of material issues.

In 2025, Porton further enhanced its ESG management through various measures. At the commitment level, our carbon reduction target has been verified by the SBTi, and we also released environmental targets covering three major areas of energy, water resources and waste management. At the management system level, we formulated Supplier Code of Conduct to further promote supply chain management. At the personnel capability level, we organized trainings on carbon verification and sustainable supply chain to improve employees’ professional skills.

Looking ahead, Porton will continue to practice the ESG development concept and promote sustainable development.

Founded in 2005, Porton Pharma Solutions Ltd. is an internationally recognized pharmaceutical contract development and manufacturing organization (CDMO) in enabling our global clients to optimize drug development and manufacturing. We provide customer development and manufacturing services for Small Molecules, Tides, Biologics and Conjugates (ADCs, AOCs, PDCs, RDCs, etc.), and Advanced Therapy Medicinal Products from pre-clinical to commercialization stages.

(博腾股份)